Literature DB >> 12739000

Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.

Frédérique Penault-Llorca1, Anne Cayre, Florence Bouchet Mishellany, Sophie Amat, Viviane Feillel, Guillaume Le Bouedec, Jean-Pierre Ferrière, Monique De Latour, Philippe Chollet.   

Abstract

Induction chemotherapy provides an excellent model for evaluation of potential predictive factors. We studied expression of SBR grade, estrogen (ER) and progesterone (PR) receptors, HER2, Ki67 and P53 on core biopsies before and after chemotherapy in a series of 115 patients, who received anthracycline-based induction chemotherapy for primary breast cancer. HER2 overexpression independently predicted response to neoadjuvant anthracycline-based chemotherapy. Patients with HER2-positive status are 4.54 times more likely to have a pathological complete response than those with negative status (p<0.005). HER2, ER and PR status were stable during treatment. P53 and Ki67 significantly increased after treatment (p<0.005 and p<0.0005). SBR grade, proliferation markers, ER evaluated before and after treatment predicted disease-free survival (DFS) in univariate analysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739000

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

Review 1.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

2.  Stability of the HER2 gene after primary chemotherapy in advanced breast cancer.

Authors:  Zsuzsanna Varga; Rosmarie Caduff; Bernhard Pestalozzi
Journal:  Virchows Arch       Date:  2005-01-14       Impact factor: 4.064

3.  HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.

Authors:  Norbert Arens; Uwe Bleyl; Ralf Hildenbrand
Journal:  Virchows Arch       Date:  2005-04-19       Impact factor: 4.064

4.  [Morphological response to therapy of breast carcinoma].

Authors:  F Länger; H-J Lück; H H Kreipe
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

5.  Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers.

Authors:  Yasuo Miyoshi; Masafumi Kurosumi; Junichi Kurebayashi; Nariaki Matsuura; Masato Takahashi; Eriko Tokunaga; Chiyomi Egawa; Norikazu Masuda; Seung Jin Kim; Masatsugu Okishiro; Tetsu Yanagisawa; Satsuki Ueda; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-16       Impact factor: 4.553

6.  Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS.

Authors:  Tessa Buckle; Joeri Kuil; Nynke S van den Berg; Anton Bunschoten; Hildo J Lamb; Hushan Yuan; Lee Josephson; Jos Jonkers; Alexander D Borowsky; Fijs W B van Leeuwen
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

7.  Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.

Authors:  Xi Jin; Yi-Zhou Jiang; Sheng Chen; Ke-Da Yu; Zhi-Ming Shao; Gen-Hong Di
Journal:  Oncotarget       Date:  2015-04-20

8.  Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer.

Authors:  Yue Zhao; Xiaoqiu Dong; Rongguo Li; Xiao Ma; Jian Song; Yingjie Li; Dongwei Zhang
Journal:  Onco Targets Ther       Date:  2015-06-19       Impact factor: 4.147

9.  Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection.

Authors:  Yunuen Alfaro; Guadalupe Delgado; Alfonso Cárabez; Brenda Anguiano; Carmen Aceves
Journal:  Mol Cancer       Date:  2013-05-24       Impact factor: 27.401

10.  Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy.

Authors:  D J Manton; A Chaturvedi; A Hubbard; M J Lind; M Lowry; A Maraveyas; M D Pickles; D J Tozer; L W Turnbull
Journal:  Br J Cancer       Date:  2006-02-13       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.